← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
OrbiMed Capital GP VIII LLC
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001845804
Purchase history
- Companies traded
- 4
- Purchases · 12M
- 3
- Purchases · 24M
- 4
- Average purchase
- $9.0M
- Median purchase
- $9.9M
- Gross purchase value
- $35.9M
Companies: BlossomHill Therapeutics, Inc. | Scribe Therapeutics, Inc. | Sionna Therapeutics, Inc. | Traws Pharma, Inc.
4 SEC accession(s) · 4 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-12 | BlossomHill Therapeutics, Inc. | BLSM | Director | $10.0M | Open filing |
| 2026-07-29 | Scribe Therapeutics, Inc. | SCTX | Director | $15.0M | Open filing |
| 2026-04-28 | Traws Pharma, Inc. | TRAW | 10% Owner | $998.2K | Open filing |
| 2025-02-10 | Sionna Therapeutics, Inc. | SION | Director | $9.9M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 50.0% (2/4) | 100.0% (2/2) | +12.1% | +12.1% | +0.0% |
| 20D | 2Small Sample | 50.0% (2/4) | 100.0% (2/2) | +51.0% | +51.0% | +34.3% |
| 60D | 0No Data | 0.0% (0/2) | — | — | — | — |
| 120D | 0No Data | 0.0% (0/1) | — | — | — | — |
Research patterns
- First purchase in 12M
- 3/3
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.